The Institute of Genetics and Cancer is a strategic partnership of the MRC Human Genetics Unit (HGU), Edinburgh Cancer Research, and the Centre for Genomic and Experimental Medicine that together form a coalition of distinct world class expertise in genetics and cancer.
The Institute of Genetics and Cancer is tackling one of the greatest biomedical challenges, determining how mutations –constitutional and acquired - drive the molecular and cellular dysfunction that result in disease. Defining the molecular mechanisms of genetic disease and cancer, and the flow of information from DNA through to the production and regulation of RNAs and proteins is critical to deliver pathways targetable by future therapies. Delivering this mission requires a critical mass of expertise to harness multiscale, multimodal and multidisciplinary approaches and research that scales from nanoscale to population; from biochemistry to in vivo; and from bedside to AI.
- Ovarian carcinosarcoma as a distinct form of ovarian cancer
- New strategy to target cancer cells expressing PD-L1
- Drivers of endocrine therapy resistance in estrogen receptor positive breast cancer
- Increased incidence of Type 1 diabetes during the COVID-19 pandemic is not a direct effect of recent COVID-19 infection
Distinguished scientists from around the world working in areas of genetics, molecular medicine and cancer relevant to our research. Student seminar blogs
Our multidisciplinary approach, researchers, collaborations and funding.
State of the art scientific facilities, infrastructure and business support.
Translating our research to maximise impact on human health.